Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of “Moderate Buy” from Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $156.60.

SRPT has been the subject of a number of analyst reports. Evercore ISI raised their price target on Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research note on Tuesday, February 20th. BMO Capital Markets began coverage on Sarepta Therapeutics in a research note on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 price target for the company. Mizuho raised their price objective on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Finally, UBS Group raised their price objective on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st.

Sarepta Therapeutics Stock Up 2.5 %

SRPT stock opened at $127.39 on Friday. The company has a quick ratio of 3.45, a current ratio of 3.95 and a debt-to-equity ratio of 1.32. The business has a 50 day moving average price of $126.22 and a two-hundred day moving average price of $110.43. The company has a market cap of $11.96 billion, a price-to-earnings ratio of -20.82 and a beta of 0.94. Sarepta Therapeutics has a twelve month low of $55.25 and a twelve month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.50. The firm had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business’s revenue was up 53.6% compared to the same quarter last year. During the same period last year, the company earned ($1.24) earnings per share. Analysts anticipate that Sarepta Therapeutics will post 2.13 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the transaction, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Stephen Mayo sold 3,135 shares of Sarepta Therapeutics stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $122.96, for a total value of $385,479.60. Following the transaction, the director now owns 6,621 shares in the company, valued at approximately $814,118.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.30, for a total value of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares in the company, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock valued at $2,739,419 in the last three months. Corporate insiders own 7.40% of the company’s stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. GAMMA Investing LLC lifted its holdings in Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares during the period. Vanguard Capital Wealth Advisors lifted its holdings in Sarepta Therapeutics by 3.8% during the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after buying an additional 90 shares during the period. DMC Group LLC lifted its holdings in Sarepta Therapeutics by 2.9% during the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after buying an additional 93 shares during the period. WCM Investment Management LLC lifted its stake in shares of Sarepta Therapeutics by 2.3% in the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares during the period. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.